Skip to main content
Top
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Hepatocellular Carcinoma | Research

Prognostic implications of alpha-fetoprotein and C-reactive protein elevation in hepatocellular carcinoma following resection (PACE): a large cohort study of 2770 patients

Authors: Kong-Ying Lin, Qing-Jing Chen, Shi-Chuan Tang, Zhi-Wen Lin, Jian-Xi Zhang, Si-Ming Zheng, Yun-Tong Li, Xian-Ming Wang, Qiang Lu, Jun Fu, Luo-Bin Guo, Li-Fang Zheng, Peng-Hui You, Meng-Meng Wu, Ke-Can Lin, Wei-Ping Zhou, Tian Yang, Yong-Yi Zeng

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Routine clinical staging for hepatocellular carcinoma (HCC) incorporates liver function, general health, and tumor morphology. Further refinement of prognostic assessments and treatment decisions may benefit from the inclusion of tumor biological marker alpha-fetoprotein (AFP) and systemic inflammation indicator C-reactive protein (CRP).

Methods

Data from a multicenter cohort of 2770 HCC patients undergoing hepatectomy were analyzed. We developed the PACE risk score (Prognostic implications of AFP and CRP Elevation) after initially assessing preoperative AFP and CRP’s prognostic value. Subgroup analyzes were performed in BCLC cohorts A and B using multivariable Cox analysis to evaluate the prognostic stratification ability of the PACE risk score and its complementary utility for BCLC staging.

Results

Preoperative AFP ≥ 400ng/mL and CRP ≥ 10 mg/L emerged as independent predictors of poorer prognosis in HCC patients who underwent hepatectomy, leading to the creation of the PACE risk score. PACE risk score stratified patients into low, intermediate, and high-risk groups with cumulative 5-year overall (OS) and recurrence-free survival (RFS) rates of 59.6%/44.9%, 43.9%/38.4%, and 20.6%/18.0% respectively (all P < 0.001). Increased PACE risk scores correlated significantly with early recurrence and extrahepatic metastases frequency (all P < 0.001). The multivariable analysis identified intermediate and high-risk PACE scores as independently correlating with poor postoperative OS and RFS. Furthermore, the PACE risk score proficiently stratified the prognosis of BCLC stages A and B patients, with multivariable analyses demonstrating it as an independent prognostic determinant for both stages.

Conclusion

The PACE risk score serves as an effective tool for postoperative risk stratification, potentially supplementing the BCLC staging system.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sung H, Ferlay J, Siegel RL, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed Sung H, Ferlay J, Siegel RL, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed
2.
go back to reference Huang DQ, Mathurin P, Cortez-Pinto H, Loomba R. Global epidemiology of alcohol-associated Cirrhosis and HCC: trends, projections and risk factors. Nat Rev Gastroenterol Hepatol. 2023;20(1):37–49.PubMedCrossRef Huang DQ, Mathurin P, Cortez-Pinto H, Loomba R. Global epidemiology of alcohol-associated Cirrhosis and HCC: trends, projections and risk factors. Nat Rev Gastroenterol Hepatol. 2023;20(1):37–49.PubMedCrossRef
3.
go back to reference Shin SW, Ahn KS, Kim SW, Kim TS, Kim YH, Kang KJ. Liver resection Versus local ablation therapies for Hepatocellular Carcinoma within the Milan Criteria: a systematic review and Meta-analysis. Ann Surg. 2021;273(4):656–66.PubMedCrossRef Shin SW, Ahn KS, Kim SW, Kim TS, Kim YH, Kang KJ. Liver resection Versus local ablation therapies for Hepatocellular Carcinoma within the Milan Criteria: a systematic review and Meta-analysis. Ann Surg. 2021;273(4):656–66.PubMedCrossRef
4.
go back to reference Zhu P, Liao W, Zhang WG, et al. A prospective study using propensity score matching to compare long-term survival outcomes after Robotic-assisted, laparoscopic, or Open Liver Resection for patients with BCLC stage 0-A Hepatocellular Carcinoma. Ann Surg. 2023;277(1):e103–11.PubMedCrossRef Zhu P, Liao W, Zhang WG, et al. A prospective study using propensity score matching to compare long-term survival outcomes after Robotic-assisted, laparoscopic, or Open Liver Resection for patients with BCLC stage 0-A Hepatocellular Carcinoma. Ann Surg. 2023;277(1):e103–11.PubMedCrossRef
5.
go back to reference Lin K, Huang Q, Wang L, et al. Pre- and postoperative models for prediction of recurrence in Non-B, Non-C Hepatocellular Carcinoma. Front Oncol. 2021;11:612588.PubMedPubMedCentralCrossRef Lin K, Huang Q, Wang L, et al. Pre- and postoperative models for prediction of recurrence in Non-B, Non-C Hepatocellular Carcinoma. Front Oncol. 2021;11:612588.PubMedPubMedCentralCrossRef
6.
go back to reference Yang P, Qiu J, Li J, et al. Nomograms for pre- and postoperative prediction of long-term survival for patients who underwent Hepatectomy for multiple Hepatocellular Carcinomas. Ann Surg. 2016;263(4):778–86.PubMedCrossRef Yang P, Qiu J, Li J, et al. Nomograms for pre- and postoperative prediction of long-term survival for patients who underwent Hepatectomy for multiple Hepatocellular Carcinomas. Ann Surg. 2016;263(4):778–86.PubMedCrossRef
7.
go back to reference Li J, Zhou J, Yang PH, et al. Nomograms for survival prediction in patients undergoing liver resection for Hepatitis B virus related early stage hepatocellular carcinoma. Eur J Cancer. 2016;62:86–95.PubMedCrossRef Li J, Zhou J, Yang PH, et al. Nomograms for survival prediction in patients undergoing liver resection for Hepatitis B virus related early stage hepatocellular carcinoma. Eur J Cancer. 2016;62:86–95.PubMedCrossRef
8.
go back to reference Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–93.PubMedCrossRef Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–93.PubMedCrossRef
9.
go back to reference Sun HC, Zhou J, Wang Z, et al. Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition). Hepatobiliary Surg Nutr. 2022;11(2):227–52.PubMedPubMedCentralCrossRef Sun HC, Zhou J, Wang Z, et al. Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition). Hepatobiliary Surg Nutr. 2022;11(2):227–52.PubMedPubMedCentralCrossRef
10.
go back to reference Wei WX, Yang ZS, Lu LH, et al. Long-term survival after partial hepatectomy for sub-stage patients with intermediate stage hepatocellular carcinoma. Int J Surg. 2018;56:256–63.PubMedCrossRef Wei WX, Yang ZS, Lu LH, et al. Long-term survival after partial hepatectomy for sub-stage patients with intermediate stage hepatocellular carcinoma. Int J Surg. 2018;56:256–63.PubMedCrossRef
11.
go back to reference Sanghera C, Teh JJ, Pinato DJ. The systemic inflammatory response as a source of biomarkers and therapeutic targets in hepatocellular carcinoma. Liver Int. 2019;39(11):2008–23.PubMedCrossRef Sanghera C, Teh JJ, Pinato DJ. The systemic inflammatory response as a source of biomarkers and therapeutic targets in hepatocellular carcinoma. Liver Int. 2019;39(11):2008–23.PubMedCrossRef
12.
go back to reference Wang Y, Peng C, Cheng Z, et al. The prognostic significance of preoperative neutrophil-lymphocyte ratio in patients with hepatocellular carcinoma receiving hepatectomy: a systematic review and meta-analysis. Int J Surg. 2018;55:73–80.PubMedCrossRef Wang Y, Peng C, Cheng Z, et al. The prognostic significance of preoperative neutrophil-lymphocyte ratio in patients with hepatocellular carcinoma receiving hepatectomy: a systematic review and meta-analysis. Int J Surg. 2018;55:73–80.PubMedCrossRef
13.
go back to reference Okamura Y, Sugiura T, Ito T, et al. Neutrophil to lymphocyte ratio as an indicator of the malignant behaviour of hepatocellular carcinoma. Br J Surg. 2016;103(7):891–8.PubMedCrossRef Okamura Y, Sugiura T, Ito T, et al. Neutrophil to lymphocyte ratio as an indicator of the malignant behaviour of hepatocellular carcinoma. Br J Surg. 2016;103(7):891–8.PubMedCrossRef
14.
go back to reference Toyoda H, Kumada T, Tada T, Sone Y, Kaneoka Y, Maeda A. Tumor markers for Hepatocellular Carcinoma: simple and significant predictors of Outcome in patients with HCC. Liver Cancer. 2015;4(2):126–36.PubMedPubMedCentralCrossRef Toyoda H, Kumada T, Tada T, Sone Y, Kaneoka Y, Maeda A. Tumor markers for Hepatocellular Carcinoma: simple and significant predictors of Outcome in patients with HCC. Liver Cancer. 2015;4(2):126–36.PubMedPubMedCentralCrossRef
15.
go back to reference Marrero JA, Feng Z, Wang Y, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology. 2009;137(1):110–8.PubMedCrossRef Marrero JA, Feng Z, Wang Y, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology. 2009;137(1):110–8.PubMedCrossRef
16.
go back to reference Sieghart W, Pinter M, Hucke F, et al. Single determination of C-reactive protein at the time of diagnosis predicts long-term outcome of patients with hepatocellular carcinoma. Hepatology. 2013;57(6):2224–34.PubMedCrossRef Sieghart W, Pinter M, Hucke F, et al. Single determination of C-reactive protein at the time of diagnosis predicts long-term outcome of patients with hepatocellular carcinoma. Hepatology. 2013;57(6):2224–34.PubMedCrossRef
17.
go back to reference Nakanishi H, Kurosaki M, Tsuchiya K, et al. Novel pretreatment scoring incorporating C-reactive protein to predict overall survival in Advanced Hepatocellular Carcinoma with Sorafenib Treatment. Liver Cancer. 2016;5(4):257–68.PubMedPubMedCentralCrossRef Nakanishi H, Kurosaki M, Tsuchiya K, et al. Novel pretreatment scoring incorporating C-reactive protein to predict overall survival in Advanced Hepatocellular Carcinoma with Sorafenib Treatment. Liver Cancer. 2016;5(4):257–68.PubMedPubMedCentralCrossRef
18.
go back to reference Nagaoka S, Yoshida T, Akiyoshi J, et al. Serum C-reactive protein levels predict survival in hepatocellular carcinoma. Liver Int. 2007;27(8):1091–7.PubMedCrossRef Nagaoka S, Yoshida T, Akiyoshi J, et al. Serum C-reactive protein levels predict survival in hepatocellular carcinoma. Liver Int. 2007;27(8):1091–7.PubMedCrossRef
19.
go back to reference Kelley RK, Meyer T, Rimassa L, et al. Serum alpha-fetoprotein levels and clinical outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in patients with Advanced Hepatocellular Carcinoma. Clin Cancer Res. 2020;26(18):4795–804.PubMedPubMedCentralCrossRef Kelley RK, Meyer T, Rimassa L, et al. Serum alpha-fetoprotein levels and clinical outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in patients with Advanced Hepatocellular Carcinoma. Clin Cancer Res. 2020;26(18):4795–804.PubMedPubMedCentralCrossRef
20.
go back to reference Notarpaolo A, Layese R, Magistri P, et al. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related Cirrhosis who had received a liver transplant for HCC. J Hepatol. 2017;66(3):552–9.PubMedCrossRef Notarpaolo A, Layese R, Magistri P, et al. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related Cirrhosis who had received a liver transplant for HCC. J Hepatol. 2017;66(3):552–9.PubMedCrossRef
21.
go back to reference Strasberg SM, Phillips C. Use and dissemination of the brisbane 2000 nomenclature of liver anatomy and resections. Ann Surg. 2013;257(3):377–82.PubMedCrossRef Strasberg SM, Phillips C. Use and dissemination of the brisbane 2000 nomenclature of liver anatomy and resections. Ann Surg. 2013;257(3):377–82.PubMedCrossRef
22.
go back to reference Tsilimigras DI, Hyer JM, Diaz A et al. Synergistic impact of alpha-fetoprotein and Tumor Burden on Long-Term outcomes following curative-intent resection of Hepatocellular Carcinoma. Cancers (Basel). 2021. 13(4). Tsilimigras DI, Hyer JM, Diaz A et al. Synergistic impact of alpha-fetoprotein and Tumor Burden on Long-Term outcomes following curative-intent resection of Hepatocellular Carcinoma. Cancers (Basel). 2021. 13(4).
23.
go back to reference Tsilimigras DI, Bagante F, Moris D, et al. Recurrence patterns and outcomes after resection of Hepatocellular Carcinoma within and beyond the Barcelona Clinic Liver Cancer Criteria. Ann Surg Oncol. 2020;27(7):2321–31.PubMedCrossRef Tsilimigras DI, Bagante F, Moris D, et al. Recurrence patterns and outcomes after resection of Hepatocellular Carcinoma within and beyond the Barcelona Clinic Liver Cancer Criteria. Ann Surg Oncol. 2020;27(7):2321–31.PubMedCrossRef
24.
go back to reference Kudo M, Izumi N, Sakamoto M, et al. Survival analysis over 28 years of 173,378 patients with Hepatocellular Carcinoma in Japan. Liver Cancer. 2016;5(3):190–7.PubMedPubMedCentralCrossRef Kudo M, Izumi N, Sakamoto M, et al. Survival analysis over 28 years of 173,378 patients with Hepatocellular Carcinoma in Japan. Liver Cancer. 2016;5(3):190–7.PubMedPubMedCentralCrossRef
25.
go back to reference Montal R, Andreu-Oller C, Bassaganyas L, et al. Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials. Br J Cancer. 2019;121(4):340–3.PubMedPubMedCentralCrossRef Montal R, Andreu-Oller C, Bassaganyas L, et al. Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials. Br J Cancer. 2019;121(4):340–3.PubMedPubMedCentralCrossRef
26.
go back to reference Scheiner B, Pomej K, Kirstein MM, et al. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score. J Hepatol. 2022;76(2):353–63.PubMedCrossRef Scheiner B, Pomej K, Kirstein MM, et al. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score. J Hepatol. 2022;76(2):353–63.PubMedCrossRef
27.
go back to reference Ji GW, Zhu FP, Xu Q, et al. Radiomic features at contrast-enhanced CT predict recurrence in early stage Hepatocellular Carcinoma: a multi-institutional study. Radiology. 2020;294(3):568–79.PubMedCrossRef Ji GW, Zhu FP, Xu Q, et al. Radiomic features at contrast-enhanced CT predict recurrence in early stage Hepatocellular Carcinoma: a multi-institutional study. Radiology. 2020;294(3):568–79.PubMedCrossRef
28.
go back to reference Ji GW, Zhu FP, Xu Q, et al. Machine-learning analysis of contrast-enhanced CT radiomics predicts recurrence of hepatocellular carcinoma after resection: a multi-institutional study. EBioMedicine. 2019;50:156–65.PubMedPubMedCentralCrossRef Ji GW, Zhu FP, Xu Q, et al. Machine-learning analysis of contrast-enhanced CT radiomics predicts recurrence of hepatocellular carcinoma after resection: a multi-institutional study. EBioMedicine. 2019;50:156–65.PubMedPubMedCentralCrossRef
29.
go back to reference Woo HG, Park ES, Cheon JH, et al. Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma. Clin Cancer Res. 2008;14(7):2056–64. Woo HG, Park ES, Cheon JH, et al. Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma. Clin Cancer Res. 2008;14(7):2056–64.
30.
go back to reference Wu C, Lin J, Weng Y, et al. Myeloid signature reveals immune contexture and predicts the prognosis of hepatocellular carcinoma. J Clin Invest. 2020;130(9):4679–93.PubMedPubMedCentralCrossRef Wu C, Lin J, Weng Y, et al. Myeloid signature reveals immune contexture and predicts the prognosis of hepatocellular carcinoma. J Clin Invest. 2020;130(9):4679–93.PubMedPubMedCentralCrossRef
31.
go back to reference Villanueva A, Hoshida Y, Battiston C, et al. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology. 2011;140(5):1501–12e2.PubMedCrossRef Villanueva A, Hoshida Y, Battiston C, et al. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology. 2011;140(5):1501–12e2.PubMedCrossRef
32.
go back to reference Sun Y, Wu L, Zhong Y, et al. Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma. Cell. 2021;184(2):404–421e16.PubMedCrossRef Sun Y, Wu L, Zhong Y, et al. Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma. Cell. 2021;184(2):404–421e16.PubMedCrossRef
33.
go back to reference Zeng J, Zeng J, Lin K, et al. Development of a machine learning model to predict early recurrence for hepatocellular carcinoma after curative resection. Hepatobiliary Surg Nutr. 2022;11(2):176–87.PubMedPubMedCentralCrossRef Zeng J, Zeng J, Lin K, et al. Development of a machine learning model to predict early recurrence for hepatocellular carcinoma after curative resection. Hepatobiliary Surg Nutr. 2022;11(2):176–87.PubMedPubMedCentralCrossRef
34.
go back to reference Daniele B, Bencivenga A, Megna AS, Tinessa V. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology. 2004;127(5 Suppl 1):108–12.CrossRef Daniele B, Bencivenga A, Megna AS, Tinessa V. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology. 2004;127(5 Suppl 1):108–12.CrossRef
35.
go back to reference Richardson P, Duan Z, Kramer J, Davila JA, Tyson GL, El-Serag HB. Determinants of serum alpha-fetoprotein levels in hepatitis C-infected patients. Clin Gastroenterol Hepatol. 2012;10(4):428–33.PubMedCrossRef Richardson P, Duan Z, Kramer J, Davila JA, Tyson GL, El-Serag HB. Determinants of serum alpha-fetoprotein levels in hepatitis C-infected patients. Clin Gastroenterol Hepatol. 2012;10(4):428–33.PubMedCrossRef
36.
go back to reference Jun CH, Ki HS, Lee KH, et al. Impact of serum C-reactive protein level on the prognosis of patients with hepatocellular carcinoma undergoing TACE. Clin Mol Hepatol. 2013;19(1):70–7.PubMedPubMedCentralCrossRef Jun CH, Ki HS, Lee KH, et al. Impact of serum C-reactive protein level on the prognosis of patients with hepatocellular carcinoma undergoing TACE. Clin Mol Hepatol. 2013;19(1):70–7.PubMedPubMedCentralCrossRef
37.
go back to reference Socha MW, Malinowski B, Puk O, et al. C-reactive protein as a diagnostic and prognostic factor of endometrial cancer. Crit Rev Oncol Hematol. 2021;164:103419.PubMedCrossRef Socha MW, Malinowski B, Puk O, et al. C-reactive protein as a diagnostic and prognostic factor of endometrial cancer. Crit Rev Oncol Hematol. 2021;164:103419.PubMedCrossRef
38.
go back to reference Dufour JF. C-reactive protein, a prognostic marker in hepatocellular carcinoma. Hepatology. 2013;57(6):2103–5.PubMedCrossRef Dufour JF. C-reactive protein, a prognostic marker in hepatocellular carcinoma. Hepatology. 2013;57(6):2103–5.PubMedCrossRef
39.
go back to reference Huang J, Baum Y, Alemozaffar M, et al. C-reactive protein in urologic cancers. Mol Aspects Med. 2015;45:28–36.PubMedCrossRef Huang J, Baum Y, Alemozaffar M, et al. C-reactive protein in urologic cancers. Mol Aspects Med. 2015;45:28–36.PubMedCrossRef
40.
go back to reference Mikkelsen MK, Lindblom N, Dyhl-Polk A, Juhl CB, Johansen JS, Nielsen D. Systematic review and meta-analysis of C-reactive protein as a biomarker in Breast cancer. Crit Rev Clin Lab Sci. 2022;59(7):480–500.PubMedCrossRef Mikkelsen MK, Lindblom N, Dyhl-Polk A, Juhl CB, Johansen JS, Nielsen D. Systematic review and meta-analysis of C-reactive protein as a biomarker in Breast cancer. Crit Rev Clin Lab Sci. 2022;59(7):480–500.PubMedCrossRef
41.
go back to reference Hashimoto K, Ikeda Y, Korenaga D, et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer. 2005;103(9):1856–64.PubMedCrossRef Hashimoto K, Ikeda Y, Korenaga D, et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer. 2005;103(9):1856–64.PubMedCrossRef
42.
go back to reference An HJ, Jang JW, Bae SH, et al. Serum C-reactive protein is a useful biomarker for predicting outcomes after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl. 2012;18(12):1406–14.PubMedCrossRef An HJ, Jang JW, Bae SH, et al. Serum C-reactive protein is a useful biomarker for predicting outcomes after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl. 2012;18(12):1406–14.PubMedCrossRef
43.
go back to reference Rekik S, Guyot E, Bhais M, et al. The CRP level and STATE score predict survival in cirrhotic patients with hepatocellular carcinoma treated by transarterial embolization. Dig Liver Dis. 2016;48(9):1088–92.PubMedCrossRef Rekik S, Guyot E, Bhais M, et al. The CRP level and STATE score predict survival in cirrhotic patients with hepatocellular carcinoma treated by transarterial embolization. Dig Liver Dis. 2016;48(9):1088–92.PubMedCrossRef
44.
go back to reference Tada T, Kumada T, Hiraoka A, et al. C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib. Sci Rep. 2022;12(1):8421.PubMedPubMedCentralCrossRef Tada T, Kumada T, Hiraoka A, et al. C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib. Sci Rep. 2022;12(1):8421.PubMedPubMedCentralCrossRef
45.
go back to reference Ridker PM. From C-Reactive protein to Interleukin-6 to Interleukin-1: moving Upstream to identify novel targets for atheroprotection. Circ Res. 2016;118(1):145–56.PubMedPubMedCentralCrossRef Ridker PM. From C-Reactive protein to Interleukin-6 to Interleukin-1: moving Upstream to identify novel targets for atheroprotection. Circ Res. 2016;118(1):145–56.PubMedPubMedCentralCrossRef
46.
go back to reference Wang Y, Li Z, Huang Z, Yu X, Zheng L, Xu J. C-Reactive protein is an Indicator of the Immunosuppressive Microenvironment fostered by myeloid cells in Hepatocellular Carcinoma. Front Oncol. 2021;11:774823.PubMedCrossRef Wang Y, Li Z, Huang Z, Yu X, Zheng L, Xu J. C-Reactive protein is an Indicator of the Immunosuppressive Microenvironment fostered by myeloid cells in Hepatocellular Carcinoma. Front Oncol. 2021;11:774823.PubMedCrossRef
47.
go back to reference Zhang Y, Lu L, He Z, et al. C-Reactive protein levels predict responses to PD-1 inhibitors in Hepatocellular Carcinoma patients. Front Immunol. 2022;13:808101.PubMedPubMedCentralCrossRef Zhang Y, Lu L, He Z, et al. C-Reactive protein levels predict responses to PD-1 inhibitors in Hepatocellular Carcinoma patients. Front Immunol. 2022;13:808101.PubMedPubMedCentralCrossRef
48.
go back to reference She S, Xiang Y, Yang M, et al. C-reactive protein is a biomarker of AFP-negative HBV-related hepatocellular carcinoma. Int J Oncol. 2015;47(2):543–54.PubMedCrossRef She S, Xiang Y, Yang M, et al. C-reactive protein is a biomarker of AFP-negative HBV-related hepatocellular carcinoma. Int J Oncol. 2015;47(2):543–54.PubMedCrossRef
49.
go back to reference Kornberg A, Schernhammer M, Kornberg J, Friess H, Thrum K. Serological risk index based on alpha-fetoprotein and C-Reactive protein to Indicate Futile Liver Transplantation among patients with Advanced Hepatocellular Carcinoma. Dig Dis Sci. 2019;64(1):269–80.PubMedCrossRef Kornberg A, Schernhammer M, Kornberg J, Friess H, Thrum K. Serological risk index based on alpha-fetoprotein and C-Reactive protein to Indicate Futile Liver Transplantation among patients with Advanced Hepatocellular Carcinoma. Dig Dis Sci. 2019;64(1):269–80.PubMedCrossRef
50.
go back to reference Yin L, Li H, Li AJ, et al. Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCT. J Hepatol. 2014;61(1):82–8.PubMedCrossRef Yin L, Li H, Li AJ, et al. Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCT. J Hepatol. 2014;61(1):82–8.PubMedCrossRef
Metadata
Title
Prognostic implications of alpha-fetoprotein and C-reactive protein elevation in hepatocellular carcinoma following resection (PACE): a large cohort study of 2770 patients
Authors
Kong-Ying Lin
Qing-Jing Chen
Shi-Chuan Tang
Zhi-Wen Lin
Jian-Xi Zhang
Si-Ming Zheng
Yun-Tong Li
Xian-Ming Wang
Qiang Lu
Jun Fu
Luo-Bin Guo
Li-Fang Zheng
Peng-Hui You
Meng-Meng Wu
Ke-Can Lin
Wei-Ping Zhou
Tian Yang
Yong-Yi Zeng
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11693-6

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine